Uterine Fibroid Treatment Devices Market – Drivers
In UK, uterine fibroid was diagnosed to 30,929 people at NHS hospital by hospital consultants in year 2012 – 2013, which is expected to drive the Uterine Fibroid Treatment Devices Market growth. According to National Uterine Fibroids Foundation in 2010, an estimated12 hysterectomies were performed in the U.S. every 10 minutes and around 600,000 hysterectomies were performed annually in the U.S. out of which around 170,000 – 300,000 were performed due to uterine fibroids, which is expected to support growth of the Uterine Fibroid Treatment Devices Market in near future.
Furthermore, according to Centers for Disease Control and Prevention (CDC) in the U.S. around 53,028 women were diagnosed with uterine cancer in 2014, which supports growth of the uterine fibroid treatment. Advancement in uterine fibroid treatment such as, minimal invasive treatment for fibroid is also expected to boost the Uterine Fibroid Treatment Devices Market growth. For instance, in 2015, FDA approved the use of Sonablate 450 by SonaCare Medical. This device is mainly indicated for trans-rectal High Intensity Focused Ultrasound (HIFU) ablation of prostatic tissue.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients